Introduction
Renal cell cancer (RCC) is a disease afflicting approximately 27,000 individuals per year in the United States [1] . It is the tenth most common cancer, constitutes 3% of all adult malignancies, affects men more than women, and occurs at a median age of 64 years. One third of the patients presents with distant metastases while 30%-40% of the others will eventually develop these [2] . The median survival of metastatic disease is 7 months and only l%-2% of patients survive 5 years or more [3] . Surgery is the standard treatment for localized disease; however, its role in the presence of distant metastases is limited to palliation of symptoms or resection of solitary metastases in highly selected patients. The role of radiotherapy is limited to palliation of symptoms, while hormonal treatment and chemotherapy are ineffective [4] , the latter possibly partly because of the high expression of the multidrug resistance (MDR1) gene in human RCC [5] .
In search for better treatment immunotherapy has also been studied extensively. The basis for this approach originated from observations that metastases though infrequently [6] , may regress following nephrectomy as a consequence of an immune response. Early attempts to induce an immune response involved application of crude tumor cell preparations, bacillus Calmette-Guerin, or Corynebacterium parvum. Such non-specific immunotherapy was proven ineffective [7] . Efforts were subsequently directed towards activation of the patients' immune system by biologic response modifiers (BRMs) or the adoptive transfer of activated immune cells. The interest in immunotherapy revived with the potentials of genetic engineering, mass cell culturing, the improved techniques in protein and nucleic acid sequencing, and hybridoma technology [8] through which highly purified molecules such as interferons, interleukins, tumor-necrosis factor and monoclonal antibodies directed against tumor-associated antigens became available. In renal cell cancer the most significant treatment results are obtained with interferons and interleukin-2. This review focuses on the use of these cytokines.
Immunomodulation with interferon
Interferons were initially identified as antiviral agents [9] , but in addition these molecules are potent regulators of cell gene expression, cell structure and cell function, and they exhibit direct antiproliferative activity. Three major classes of interferons have been characterized: Interferon-alpha (IFN-a) produced by leukocytes, interferon-beta (IFN-p) produced by fibroblasts, lymphoblastoid cells, macrophages and epithelial cells, and interferon-gamma (IFN-Y) produced by activated lymphocytes. Interferons have antitumor properties, either mediated through a direct cytotoxic effect on tumor cells, augmentation of the immunogenicity of tumors by upregulation of major histocompatibility complex (MHC) and tumor-associated antigens, and/ or activation of macrophages, T-lymphocytes, and natural killer (NK) cells.
Initially, human leukocyte derived IFN-a was used [10] [11] [12] , yielding response rates not exceeding 15% in patients with renal cell cancer. The development of recombinant DNA techniques made it possible to develop highly purified preparations with considerable biologic activity. Studies using IFNa-2a have shown response rates of approximately 15% (a total of 420 patients; 95% confidence interval (CI): 12%-19%) [13] [14] [15] [16] [17] [18] [19] [20] [21] . With IFNa-2b similar response rates have been reported (239 patients; 95% CI: 12%-22%) [17, [22] [23] [24] [25] . The experience with IFN-p in renal cell cancer is very limited (response rate of 7% in only 28 patients) [26, 27] . IFN-Y yielded a 10% response rate (255 patients; 95% CI: 6%-14%) [23, [28] [29] [30] [31] [32] [33] [34] [35] [36] . In most series, patients with a good performance status, low tumor burden or mainly lung metastases were more likely to respond to IFN. The time to response varied from 1-3 months, the median duration of response was 6 months. Survival data vary from [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] + months and are likely to be influenced by patient selection [15, 37] .
In a meta-analysis of 1600 RCC patients, treatment with IFN resulted in a response rate of 15% including 2% complete responses [38] . Approximately 3% of responding patients survived for prolonged periods without additional therapy. Selection bias and small sample size may account for much of the variability in reported response rates.
Although the optimal dose and schedule of IFN-a has yet to be determined, in 2 small randomized trials the highest therapeutic index was achieved with a total daily dose of 5-10 MU [12, 13, 39] . The route of administration (s.c. or i.v.) does not seem to be a major factor in determining response.
Side effects of interferon therapy are proportional to dose, more pronounced in elderly patients and fully reversible [40] . Acute effects involve an influenza-like syndrome, characterized by fever, chills, tachycardia, malaise, myalgia, headache, dizziness, but dissipate after 1 week of continued therapy. Chronic effects involve primarily fatigue, weakness, and anorexia, which have been dose-limiting in the majority of trials. Other common and usually mild side effects include decreased ability to concentrate, nausea, emesis, diarrhea, elevation of liver enzymes, proteinuria, alopecia, anemia, leukopenia, and thrombocytopenia [40] . Moderate to severe changes in behavior are possibly due to direct effects of IFN on the brain [41, 42] . Toxicity can be reduced by using induction treatment with relatively high dose over a short period of time followed by maintenance therapy with a lower dose [15] . Patients can be treated symptomatically with acetaminophen and benzodiazepines. The development of neutralizing antiinterferon antibodies in patients during therapy with IFN has been described. The observed frequency showed a wide range, varying from 5% to 44% [13, 22, 43, 44] . The clinical relevance of these antibodies remains controversial and further investigations are necessary to determine the effect of their formation on antitumor response.
It has been suggested that treatment results with IFN-a may be improved by the addition of cytotoxic drugs, in particular vinblastine, which is considered to have some activity in RCC [46] . However, while response rates in relatively small non randomized studies range from 0%-45%, a randomized study [47] could not show any benefit of adding vinblastine to IFN-a.
In conclusion, single agent therapy with interferon in metastatic renal cell cancer manifests modest clinical antitumor activity. It is not clear whether any one IFN preparation or dosage scheme is superior, nor is there definitive evidence for the superior efficacy of interferon combinations or interferon in conjunction with chemotherapy.
The interleukins
The interleukins are mediators secreted by a variety of cell types that can activate and regulate growth and/or differentiation of immune cells. Through recombinant DNA technology the list of known, well-characterized, multifunctional interleukins has extended steadily. To date, 15 interleukins have been identified and cloned (Table 1 ). The availability of purified, recombinant interleukins has enabled extensive in vitro and in vivo studies, to characterize their biologic effects and mechanisms of action. This has considerably enhanced our understanding of how these multifunctional cytokines regulate immune-, hematopoietic-and inflammatory processes, through binding to unique cell surface receptors. In most instances the action of one particular cytokine can cause a cascade of events in which complex interactions between a number of distinct secondarily secreted cytokines and effector cells occur. The interleukins, their sources and biologic effects are depicted in Table 1 .
Some of the interleukins may have a direct or indirect inhibitory effect on tumor growth (e.g., by activation of T-lymphocytes or macrophages) and thus may be useful for cancer therapy. Immunotherapy of RCC is predominated by interleukin-2 (IL2) so we focus on this cytokine in the framework of this review.
Immunomodulation with IL2
LL2, first described in 1976, is a glycoprotein lymphokine mainly produced by T-lymphocytes of the helper subset [51] [52] [53] . IL2 induces proliferation of antigen stimulated T-cells and, at high concentration, non-specific lymphokine-activated killer (LAK) cells. When appropriately activated, the expansion of T-cells in the presence of IL2 can be maintained in culture systems for many weeks or months. IL2 is also the predominant cytokine activating NK cells to fully function and Deactivated NK cells lyse fresh syngeneic NK-resistant murine and human tumor cells [94, 95] .
IL2 was also used to grow lymphocytes directly from the peripheral blood or spleen. Proliferating lymphocytes could be identified by their ability to lyse fresh tumor cells but not fresh normal cells, the socalled LAK phenomenon. These LAK cells were initially distinguished from NK cells since they could be derived from sites where NK activity was not usually found such as thoracic duct fluid, whereas LAK could also kill fresh tumors which were resistant to NK lysis [96] [97] [98] . It is now clear that the majority of cells with LAK activity are large granular lymphocytes (LGLs) that do not bear B-cell and T-cell receptors or have functional rearrangements of the T-cell receptor genes. Such cells are capable of mediating NK activity, LAK activity, antibody-dependent cellular cytotoxicity, and are capable of secreting a variety of cytokines [99] [100] [101] .
LL2 mediates its effects via specific cell surface receptors. Constitutive expression of the LL2 receptor Stimulates T-cell proliferation; induces LAK-cells; interacts with the beta 92, 93 chain of the IL2 receptor (EL2R) beta chain is observed on macrophages. Antibodies blocking IL2 interaction with this chain prevent IL2 induced cytolytic maturation of macrophages but not the lytic activity induced by interferon-y. Stimulation of macrophages with IL2 causes them to release large quantities of TGF0 [102, 103] an important physiological, antagonistic regulator of tumor necrosis factor (TNF) synthesis and action. Multiple other cell types have been reported to express the beta chain of the EL2 receptor. Much of the effect of IL2 on other cell types is mediated by the production of other cytokines, subsequent to IL2/IL2R interaction.
LL2 treatment induces alteration in circulating neutrophil Fc-receptor expression as well as reduction in chemotactic activity [104, 105] , which leads to a marked increase of the risk of catheter-related infections in IL2 treated patients, which requires prophylactic use of antibiotics and/or tunneled catheters [106, 107] . In addition, probably partly due to the induction of IL5, IL2 administration causes an increase in circulating eosinophils [108] , which are capable of cytolysis of NK susceptible targets.
High-dose bolus intravenous IL2
The initial experience with EL2 in humans was obtained with a regimen of intravenous bolus therapy given every 8 hours, which was developed by Rosenberg et al. [109] . Limited phase I studies demonstrated that the maximum tolerated dose (MID) of this schedule of IL2 was 600,000-720,000 nj/kg, given for 14-20 doses [110] . This regimen of high-dose bolus IL2 has yielded an overall response rate in metastatic RCC of 20%, comprising 7% CRs and 13% PRs [110] . A summary of the literature on the treatment of RCC with high-dose bolus IL2 alone is shown in Table 2 . The overall response rate in these studies was 15% [110] [111] [112] [113] [114] .
High-dose bolus IL2 is associated with considerable toxicity and frequently requires intensive care management. The most striking side effects are a capillary leak syndrome and decreased peripheral vascular resistance, leading to interstitial and peripheral edema, hypotension and oliguria. In addition, IL2 can cause flu-like symptoms as described in the chapter on EFNs. Hence, dose reductions and treatment interruptions are necessary in 40%-50% of patients. Based on growing experience, it has been suggested to reserve high-dose bolus IL2 for patients in good condition, with normal cardiac, pulmonary, renal and hepatic function. Although concern has been expressed that dose reduction may decrease the efficacy of IL2, there is no evidence to suggest that the response rates are indeed reduced. Yang et al. [115] performed a randomized trial comparing a high-dose bolus IL2 regimen (720,000 IU/kg i.v. every 8 hours), with a low-dose bolus schedule (72,000 IU/kg i.v. every 8 hours). The high-dose arm was associated with significantly more toxicity. The respective response rates were 15% for the low-dose regimen and 20% for the high-dose regimen. There was no difference in survival.
Overall, IL2 induces objective responses in 15%-20% of patients with metastatic renal cell cancer. Although these response rates are not different from the results obtained with IFNs, approximately 1/3 of responders achieve a complete response, and moreover responses to IL2 appear to last longer. Some of the patients in the early studies are now disease-free for more than 7 years, and thus it is conceivable that they have been cured.
High-dose continuous intravenous IL2 infusion (c.i. v.)
In an effort to reduce the toxicity related to high-dose bolus IL2, continuous intravenous (c.i.v.) infusion has been studied. Some of these studies have suggested that c.i.v. IL2 produces greater immunostimulatory effects such as greater rebound lymphocytosis, LAK-cell yield, and in vivo immunostimulation [116, 117] .
West et al. reported that the antitumor effects of c.i.v. IL2 were similar to those obtained with high-dose bolus IL2 [118] . Toxicity appeared to be somewhat less with c.i.v. than with high-dose bolus IL2. With c.i.v. IL2 response rates of approximately 15%-20% are achieved. The results of the most important trials are summarized in Table 3 .
The overall response rates and types of side effects are similar for high-dose bolus IL2 and high-dose c.i.v. IL2. The only randomized trial comparing bolus IL2 to c.i.v. IL2 was conducted by Weiss et al. [124] . Fortyeight patients received EL2 by c.i.v. at a dose of 18-22.5 MIU/m 2 /day, and 46 patients received 600,000 IUAg (» 24 MIU/m 2 ) of IL2 every 8 hours by i.v. bolus, i.e., a 3-fold difference in total dose per course in favor of bolus administration. Infections were more frequent in patients on ci.v. IL2, while thrombocytopenia was more frequent in patients on bolus IL2. Response rates (15% and 20%, respectively) were not significantly different. Another conclusion from these studies was that the cumulative MTD of IL2 is less for c.i.v. administration than for bolus administration.
Subcutaneous IL-2 administration
After subcutaneous (s.c.) administration, many biological response modifiers yield sustained blood levels for up to 24 hours. Therefore, some investigators explored the s.c. route of administration in order to simplify IL2 therapy and to reduce side effects (Table 4 ). This treatment can be given on an outpatient basis. Buter et al. [126] administered IL2 s.c. once daily for 5 days a week for 6 weeks. The resulting 20% response rate could not be confirmed by others using comparable doses and regimens [127, 128] . Several studies have combined IL2 s.c. with IFNa. The reported response rates varied from 12%-25% [127, 129, 130] . Clearly, the toxicity of s.c. IL2 is modest in comparison with the intravenous route and mostly consist of local inflammation at the injection site and flu-like symptoms.
In summary, low-dose s.c. IL2 regimens have modest antitumor activity and may be an option with greater safety indicated for patients with concomitant disease such as cardiovascular abnormalities. However, antd- 14 (27) 127 17 (49) 127 49 (22) tumor effects are difficult to interpret, because most reported studies are small phase I-II trials.
Combination therapy
The rationale for using combinations of different cytokines is the observation that some of these agents such as IL2 and IFN-a have shown synergistic antitumor activity against a variety of tumors in preclinical studies [131] [132] . In many weakly or non-immunogenic tumors, the combination of IL2 and IFN-a has shown substantial antitumor activity in settings where either agent alone is ineffective. Despite the enhancing effect of interferons on class I MHC expression, the ability of EFN to enhance the activity of IL2 appears more dependent on NK cells, since the synergy between the two cytokines is decreased in NK-deficient beige mice and in mice depleted of NK cells [132] . Synergy between IL2 and interferon in murine models is not restricted to antitumor activity, but pertains to toxicity as well [135, 136] . Many clinical trials have been performed to evaluate combinations of IL2 and IFN-a. Rosenberg et al. used a high-dose regimen of bolus intravenous IL2 given every 8 hours for 5 days, week 1 and 3, at doses ranging from 3-13.5 MIU/m 2 , combined with IFN-a 3 MU/m 2 intravenously. At the highest dose levels of this study response rates of 38% for RCC were observed [137] . However this high-dose schedule of the 2 cytokines appeared to result in increased cardiac-, neuropsychiatric-, and hepatic toxicity [143, 155] . Therefore, subsequent trials attempted to decrease toxicity by administering lower dosages. Numerous doses and schedules of IL2 and IFN-a have been tested. Intermediate to high dose schedules yielded response rates of approximately 16% [112, 138-142, 144-148, 155] . A summary of these trials is given in Table 5 .
Several small studies have focused on outpatient low-dose regimens [129, [149] [150] [151] [152] [153] [154] . Although these regimens produce less acute toxicity and are therefore easier to administer than high-dose IL2 regimens, most patients developed chronic fatigue and a decrease in performance status requiring modification or cessation of therapy.
The Surgery Branch of the National Cancer Institute -USA has reported the long-term follow-up evaluation of their initial phase I/n study [137] and concluded that the combined use of IL2 and IFN-a was not indicated based on a lack of survival benefit and increased toxicity [155] . These findings are in agreement with those of a randomized study comparing IL2 + IFN-a versus IL2 alone [112] . In this trial IL2 alone resulted in a response rate of 17%, while the combination yielded a response rate of 11%. The median survival in the 2 treatment arms was 15, 5 months and 16 months, respectively.
Presently, an interesting area of research involves the application of chemo-immunotherapy. Several investigators have added 5-fluorouracil (5-FU) to the combination of IL2 and IFNa and reported response rates varying from 24%-49% [127, 156, 157] . Whether the addition of 5-FU to IL2/IFN-a represents a benefit will have to be addressed in randomized studies.
The combination of IL2 and IFN-y has also been used in the treatment of RCC. Although IFN-y was not able to increase EL2 receptor expression, it did increase serum p-2-microglobulin levels [159] , IL2 receptors on T-cells, HLA-DR expression on NK cells, and Fc receptors on macrophages [160] . Increases of LAK and NK activity correlated with absence of disease progression [160] . IFN-y appeared not to worsen IL2 toxicity, but early clincal studies have shown poor treatment results, so that the combination of IL2 and IFN-y has not been elaborated [159, 163] .
Studies on the combination of IL2 with IL4, intended to synergjze the activation and proliferation of MHC-restricted cytotoxic T-lymphocytes, failed to (16) 32 (17) 89 (23) demonstrate enhancement of immune stimulation or antitumor effect [164] [165] [166] [167] .
In tumor bearing animals interesting though unexplained synergistic antitumor effects have been demonstrated with the combination of TNFa and EL2 with a clear dose and schedule dependency [168] [169] [170] . Optimal results have been obtained when TNFa was used at its MTD prior to IL2 administration [169] . Clinical trials have shown that administration of TNF-a prior to IL2 did not appear to increase the toxicity of IL2, while administration of IL2 prior to or concurrent with TNFa appeared to worsen the side effects typical of highdose IL2 [171] [172] [173] [174] . Although responses were seen, there was no evidence to suggest improved efficacy in comparison to IL2 alone.
In summary combination cytokine therapy failed to improve the clinical efficacy of IL2 alone despite promising preclinical data. 
ACIT with LAK
The cultivation of peripheral blood lymphocytes (PBL) in media containing IL2 (usually at concentrations of 6000 IU/ml) results in the generation of LAK cells. LAK is best considered as a functional state of immune cells which may be generated from both NK cell and T-lymphocyte populations [175] .
After it was demonstrated that large numbers of in vitro activated cells could safely be infused in humans, various clinical studies of IL2 and LAK with or without IFNa have been performed. These trials used a variety of regimens. The response rates ranged from 9%-34% (mean 22%) [120, [123] [124] [125] [177] [178] [179] [180] [181] . These studies are summarized in Table 6 .
In general, the addition of LAK cell infusion to highdose IL2 therapy has not been shown to be superior over single agent high-dose IL2. Three randomized trials have been carried out to determine whether the addition of LAK offers a therapeutic benefit, but none showed a higher response rate or longer survival [111, 177, 182] . The reasons for this may be various. LAK cells were shown not to localize selectively in tumors [183, 187] . In addition, the therapeutic effect of LAK is probably related to the cytotoxic effects of tumor specific T-lymfocytes at the site of the tumor [184, 188] . Immunophenotypic analysis of cellular infiltrates of regressing melanoma lesions revealed the presence of CD3 + but not CD3" CD16 + infiltrating cells, suggesting that T-lymphocytes rather than NK cells were responsible for the antitumor effect [185, 186] . Taken together, these findings indicate that direct (IL2 mediated) or indirect (through release of secondary cytokines) activation of tumor-specific T-cells form the basis of adoptive cellular immunotherapy of cancer.
ACIT with TIL
Another population of cytolytic lymphocytes, that can be used as effector cells in combination with IL2, are tumor-infiltrating lymphocytes (TIL). These immune cells possess potent antitumor activity and are derived from lymphocytes which have infiltrated tumor lesions. In contrast to LAK, murine and human TIL demonstrate cytolytic specificity only against the tumor from which they are derived or against closely related tumors [189, 190] . In murine systems TILs are 50-100 times more potent than LAK in their cytolytic capacity [189] . Murine TILs are predominantly CD3 + CD4" CD8 + , while human TILs are phenotypically more heterogenous, which may reflect the difficulties encountered in obtaining true TTL from human tumors, which by definition also contain other PBLs. This heterogeneity may be the reason that in vitro cytotoxicity of TIL is not a good predictor for their ability to cause tumor regression in vivo [191] . An exception to this rule are TILs (18) 7 (15) 6 (26) 14 (33) 8 (20) 23 (34) 101 (22) References 177  120  125  178  124  179  123   180 derived from melanomas, which manifest MHC-restricted interactions with tumor targets in at least 50% samples. TELs with specific lytic activity for autologous tumor but not for normal autologous tissues or for allogeneic tumor can be derived from approximately onethird of all patients with melanoma [191, 192] . For this reason, clinical trials of TILs in humans have concentrated on melanoma and response rates of 20%-30% have been reported [125, [193] [194] [195] . In RCC the experience with TIL is very limited and antitumor responses are rare [193, [195] [196] [197] . The same holds true for small studies with TILs and IL2 in combination with IL4 or IFNa [198] [199] [200] .
Future perspectives
From the above reviewed literature it becomes clear that no standard immunotherapy of RCC can be recommended, since the cytokines and effector cells mentioned do not offer clearcut benefit for larger groups of patients. However, it is for the first time in the long history of immunotherapy that treatment strategies can be rationally designed on the basis of our increased knowledge of the function of the immune system and its interaction with tumor target cells, whereas at the same time these strategies can be materialized with the help of recently developed methods of molecular engineering.
What is clearly needed in the clinical arena is the development of efficient effector cells which are tumor selective. Although T-lymphocytes are equipped with T-cell receptors which can recognize and bind TAA, this is clinically futile since tumor cells often do not express their TAA adequately in association with MHC molecules, which makes recognition by the T-cell receptor impossible. The CD3 antigen is an activation molecule physically associated with the T-cell receptor. Binding of the CD3 antigen to TAA leads to activation of the T-cell, followed by lymphokine production and cytolytic activity [211] . This approach of targeting immune cells to tumor cells has been elaborated in preclinical and clinical studies.
ACIT with T-lymphocytes retargeted with bispecific monoclonal antibodies
Bispecific monoclonal antibodies (bs-MAb) are hybrid antibodies constructed from two parent MAbs: one specific for the immune effector cell and the other specific for a TAA on the target cell. Bs-MAb-mediated cross-Unking of the effector T-cell to the tumor target cell results in activation of the lymphocyte leading to lysis of the tumor cell [201] [202] [203] [204] [205] 211] . Bs-MAbs are usually constructed by somatic hybridization of 2 mouse hybridomas. Several bs-MAbs have been developed with specificity against RCC, ovarian cancer and breast cancer .
One of the first clinical trials testing this concept was in ovarian cancer with a bs-MAb against the overexpressed folate-binding protein on the tumor cells and against the activation antigen CD3 [206] [207] [208] . A clinical phase I-II study was carried out in ovarian cancer patients with recurrent disease confined to the peritoneal cavity. Patients were treated with daily intraperitoneal infusions of autologous in vitro expanded T-lymphocytes retargeted with the bs-MAb. Infusions were given with low-dose IL2. The overall intraperitoneal response rate was 27% [209] . The development of neutralizing human anti-mouse antibody (HAMA) was observed in all patients after approximately 2-3 weeks from the start of treatment [210] . The use of mouse monoclonal antibodies has several disadvantages such as a short serum half-life, limited potential to trigger human effector cell functions and HAMA response [217] [218] [219] . These problems have led to the construction of 'humanized' antibodies, which have been shown to be less immunogenic than their murine counter parts [220] [221] [222] [223] .
However, despite this improvement in antibody technology, the use of bs-MAbs can still be hampered by the inaccessibility of solid tumor to antibody penetration. In addition, bs-MAb redirected T-cells retain the antibody for limited periods of 48-69 hours due to dissociation from the T-cell surface. It has also been demonstrated that bs-MAb redirected T-cells lose their signal transducing and lyric capacity following target cell recognition [209, 224] . To circumvent the limitations associated with bs-MAb, a new approach has been adopted in which T-cells are 'gene-grafted' with a permanent antibody dictated specificity.
Gene modified chimeric T-cell receptor
By the construction of a chimeric immunoglobin T-cell receptor complex (Ig-TCR), tumor selectivity of T-lymphocytes may be obtained. To be effective such T-lymphocytes would require stable expression of the engineered Ig-TCR receptor at the lymphocyte surface and its functional association with the CD 3 signal-transducing element This has been achieved by the introduction and expression of chimeric Ig/TCR genes, in which the variable (V) gene segments of the TCRa and TCRP chains are replaced by the variable gene segments of the heavy and light chain of an Ig with known specificity [225] [226] [227] [228] [229] [230] . Retroviral gene transfer is employed to transduce the chimeric receptor into activated T-lymphocytes. The transduced T-lymphocytes stably express the receptor for >4 months of in vitro culture [230] . Stimulation of the chimeric receptor results in T-cell activation, cytokine production and lysis of target cells [228] [229] [230] .
In contrast to BsMAbs redirected lymphocytes, lymphocytes transduced with chimeric Ig-TCR genes show recycling of the cytolytic process [230] . An essential feature of Ig-TCR targeted lymphocytes is their ability to recognize tumor-associated antigens in a MHC-unrestricted manner.
Cytokine gene modified tumor cells
Cytokines provide costimulatory signals important for T-lymphocyte activation. Because most cytokines have a short serum half-life, local delivery may be attractive and in addition potentially less toxic. One locoregional approach is to introduce genes encoding for cytokines into tumor cells sothat the cytokine is continuously secreted by the tumor cell, resulting in effective cytokine concentrations in the vicinity of tumor cells and tumor antigens, but not elsewhere in the body. Many cytokine genes have been introduced into tumor cells with varying effects on both tumorigenicity and immunogenicity. This new tumor vaccine approach has been best developed in murine models [231] [232] [233] [234] [235] . Pilot studies of cytokine transfer by vaccination with engineered tumor cells in patients have started [236, 237] . However, adequate TAA expression and recognition remains a problem [238] .
Cytokine gene modified effector cells
Although it has been relatively easy to express cytokine genes in tumors cells, this is not the case in lymphocytes, where it is difficult to achieve constant high levels of cytokine production, which is probably due to regulatory mechanisms [239] . Moreover, large numbers of T-cells are required for adoptive therapy, and consequently, a high transduction efficiency is needed to enable the growth of adequate numbers of gene modified cells. Recently, gene therapy of RCC has focused on TNF gene transfer into TTL [240] .
There are other possibilities for the introduction of cytokine genes into TIL. For example, TIL transduced with the gene for the IL2 receptor may increase their sensitivity to IL2. The introduction of IFN-a or EFN-y genes into TTL could cause direct antiproliferative effects and upregulation of MHC antigens, increasing the immunogenicity of the tumor. However, it should be remembered that the existence of true TIL in RCC is still controversial.
Tumor vaccines
Active specific immunotherapy with vaccines constructed of TAA is conceptually an attractive approach to treatment and possibly to prevention of cancer. The rationale is that such vaccines may be able to stimulate the immune system more vigorously and activate silent precursor lymphocytes with tumor specificity. However, in most types of human cancer, there is little evidence that primary or metastatic tumors induce immunity in patients. Occasionally, melanoma patients were found to have demonstrable tumor specific antibodies and cytotoxic T-lymphocytes [241] [242] [243] . The problem with human tumors appears to be poor immunogenicity of relevant antigens which permits rumor cells to escape the immune attack and active inhibition of the host immune response by the tumor cells [244] . Thus far, a number of antigens have been identified as targets for recognition by cytotoxic lymphocytes, mostly in melanoma, but also in other tumors types [245] [246] [247] [248] [249] [250] [251] . Vaccination studies with immunogenic peptides in humans have recently started [252, 253] .
It can be concluded that the past 15 years have witnessed revolutionary developments in tumorimmunology and experimental immunotherapy. Firstly, our understanding of the communication network between immune cells has significantly increased. Secondly, the availability of recombinant DNA techniques has enabled the isolation and production of a whole series of interleukins which can be studied in preclinical and clinical models. Finally, new and refined methods of tumor specific targeted immunotherapy are on the brink of clinical application.
